Clinical Trials Logo

Hyperoxaluria clinical trials

View clinical trials related to Hyperoxaluria.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06138327 Recruiting - Kidney Stone Clinical Trials

A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria

Start date: September 26, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety of BMN 255 and to learn about the effect BMN 255 has on you and your hyperoxaluria associated with NAFLD, and compare these effects with a placebo. The primary safety objective of the study is to assess the safety and tolerability of daily oral doses of BMN 255 in adult participants with NAFLD and hyperoxaluria. The primary efficacy objective of the study is to assess 24-hour urine oxalate levels (24-hour urine collection corrected for BSA) following daily oral doses of BMN 255 in adult participants with NAFLD and hyperoxaluria.

NCT ID: NCT03346369 Recruiting - Nephrolithiasis Clinical Trials

Lanthanum Carbonate (Fosrenol®) to Reduce Oxalate Excretion in Patients With Secondary Hyperoxaluria and Nephrolithiasis

LaCa
Start date: August 18, 2017
Phase: Phase 3
Study type: Interventional

This study investigates the efficacy and the safety of Lanthanum Carbonate for the reduction of urinary oxalate excretion in patients with secondary hyperoxaluria and nephrolithiasis.

NCT ID: NCT02780297 Recruiting - Cystinuria Clinical Trials

Prospective Research Rare Kidney Stones (ProRKS)

ProRKS
Start date: May 2016
Phase:
Study type: Observational

The purpose of this study is to determine the natural history of the hereditary forms of nephrolithiasis and chronic kidney disease (CKD), primary hyperoxaluria (PH), cystinuria, Dent disease and adenine phosphoribosyltransferase deficiency (APRTd) and acquired enteric hyperoxaluria (EH). The investigator will measure blood and urinary markers of inflammation and determine relationship to the disease course. Cross-comparisons among the disorders will allow us to better evaluate mechanisms of renal dysfunction in these disorders.